Xiaomi Shares Jump on Europe EV Expansion Plan 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Add as a preferred source on Google
WALTHAM, Mass., March 06, 2018 -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) a clinical-stage biopharmaceutical company developing novel read-through drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases, today announced that Chairman and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. EST at the Boston Marriott Copley Place.
A live audio webcast witll be available on the “Events & Presentations” section of the Company's investor website at www.radiuspharm.com, where a replay will also be available following the presentation.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
Contact:
Barbara Ryan
203-274-2825
[email protected]
